Signal from the log
TriGemX Bio
94 M$ · Undisclosed · United States · Biotech
TriGemX Bio, nouveau nom de Kallyope, développe elismetrep, un comprimé qui bloque le canal TRPM8 des nerfs de la face pour traiter la crise de migraine. La levée finance deux essais de phase 3, dont le premier résultat est attendu mi 2027.
Article
Announced on , logged by the watch of 1 October 2026.
- Operation
- Funding round
- Announced amount
- 94 M$
- Stage
- Undisclosed
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by The Column Group , TCGX , Viking Global Investors
Provenance
Source businesswire,endpoints
Logged on 1 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.